Tauromustine (BioDeep_00000655819)
代谢物信息卡片
化学式: C7H15ClN4O4S (286.05025)
中文名称: 牛磺莫司汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O
InChI: InChI=1S/C7H15ClN4O4S/c1-11(2)17(15,16)6-4-9-7(13)12(10-14)5-3-8/h3-6H2,1-2H3,(H,9,13)
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- B Hartley-Asp, K Hansson, J Vibe-Petersen, H H Hansen, J Polacek, M Ellman, P O Gunnarsson. Chromosome aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose.
Cancer chemotherapy and pharmacology.
1996; 38(4):309-16. doi:
10.1007/s002800050488. [PMID: 8674152] - S R Hill, M C Bibby. 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice.
Cancer chemotherapy and pharmacology.
1994; 34(1):57-62. doi:
10.1007/bf00686112. [PMID: 8174203] - M I Walash, F Belal, M E Metwally, M M Hefnawy. Fluorimetric determination of tauromustine (a novel antitumour agent) in formulations and biological fluids.
Journal of pharmaceutical and biomedical analysis.
1993 Aug; 11(8):777-80. doi:
10.1016/0731-7085(93)80188-7. [PMID: 8257744] - G Roos, P I Christensson, I A el Hag, B Jakobsson, H Teder, U Stenram. Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069.
Anticancer research.
1993 May; 13(3):635-41. doi:
. [PMID: 8317891] - M C Bibby, P M Loadman, A F al-Ghabban, J A Double. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
British journal of cancer.
1992 Mar; 65(3):347-50. doi:
10.1038/bjc.1992.70. [PMID: 1558786] - I R Whittle, J S MacPherson, J D Miller, J F Smyth. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.
Journal of neurosurgery.
1990 May; 72(5):721-5. doi:
10.3171/jns.1990.72.5.0721. [PMID: 2157825] - J Seidegård, L Grönquist, P O Gunnarsson. Metabolism of a novel nitrosourea, tauromustine, in the rat.
Biochemical pharmacology.
1990 May; 39(9):1431-6. doi:
10.1016/0006-2952(90)90424-j. [PMID: 2334443] - J Polacek, B Gustafsson, S Brandin, A Ottersgård-Brorsson. Determination of tauromustine and its demethylated metabolites in plasma and urine.
Journal of chromatography.
1990 Mar; 526(1):151-7. doi:
10.1016/s0378-4347(00)82492-5. [PMID: 2341526] - A T Van Oosterom, J P Droz, S T Fossa, A V Bono, T A Splinter, A J Verbaeys, J Keizer, M De Pauw, R Sylvester. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
European journal of cancer & clinical oncology.
1989 Dec; 25(12):1889-90. doi:
10.1016/0277-5379(89)90365-9. [PMID: 2632270] - P O Gunnarsson, J Vibe-Petersen, J S Macpherson, P S Warrington, J Polacek, M Ellman, H H Hansen, J F Smyth. Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
Cancer chemotherapy and pharmacology.
1989; 23(3):176-80. doi:
10.1007/bf00267951. [PMID: 2924375] - J A Double, M C Bibby, P M Loadman, J C Bloomer. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.
European journal of cancer & clinical oncology.
1988 Aug; 24(8):1355-60. doi:
10.1016/0277-5379(88)90228-3. [PMID: 3181256] - R J Fergusson, L E Anderson, J S Macpherson, P Robins, J F Smyth. Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.
British journal of cancer.
1988 Apr; 57(4):339-42. doi:
10.1038/bjc.1988.78. [PMID: 3390369] - J Polacek, P O Gunnarsson, S Brandin. Determination of tauromustine, a nitrosourea-based antitumour agent, in plasma by high-performance liquid chromatography.
Journal of chromatography.
1988 Mar; 425(2):424-8. doi:
10.1016/0378-4347(88)80050-1. [PMID: 3372655] - J G Heaf, M Hansen. Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate.
Acta medica Scandinavica.
1988; 224(3):287-8. doi:
10.1111/j.0954-6820.1988.tb19375.x. [PMID: 3239457] - J F Smyth, J S Macpherson, P S Warrington, M E Kerr, J M Whelan, M A Cornbleet, R C Leonard. Phase I study of TCNU, a novel nitrosourea.
European journal of cancer & clinical oncology.
1987 Dec; 23(12):1845-9. doi:
10.1016/0277-5379(87)90050-2. [PMID: 3436348] - I R Whittle, J S Macpherson, J Smyth, J D Miller. Experimental cerebral and plasma pharmacokinetic studies of TCNU: implications for brain tumour chemotherapy.
British journal of neurosurgery.
1987; 1(3):365-8. doi:
10.3109/02688698709023779. [PMID: 3268132]
